Impact of hemoglobin level on survival in definitive chemoradiotherapy for T4/M1 lymph node esophageal cancer

Diseases of the Esophagus

Volumn 21, Issue 3, 2008, Pages 195-200

  Zenda, S ^a   Hironaka, Shuichi ^a   Boku, N ^a   Yamazaki, K ^a   Yasui, H ^a   Fukutomi, A ^a   Yoshino, T ^a   Onozawa, Y ^a   Nishimura, T ^a  

^a SHIZUOKA CANCER CENTER   (Japan)

Author keywords

Chemoradiotherapy; Complete response; Endoscopy; Esophageal cancer; Hemoglobin

Indexed keywords

CISPLATIN; CREATININE; FLUOROURACIL; HEMOGLOBIN;

ADULT; AGED; ANEMIA; AORTA PERFORATION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DRUG FATALITY; EFFUSION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGITIS; ESOPHAGUS RESECTION; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; LEUKOPENIA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; NAUSEA; NEUROPATHY; PERICARDITIS; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; RADIATION INJURY; SENSORY NEUROPATHY; SEPSIS; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR VOLUME;

AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; FEMALE; HEMOGLOBINS; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 42649135588     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2007.00750.x     Document Type: Article

References (45)

1. Editorial Board of the Cancer Statistics in Japan (ed.). Cancer statistics in Japan 2001. Tokyo: Foundation for promotion of cancer research, 2001.
2. Herskovic A, Martz L K, Al-Sarraf M et al. Combination chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992; 326: 1593-8.
3. Al-Sarraf M, Martz K, Herskovic A et al. Progress report of combined chemo-radiotherapy vs radiotherapy alone in patients with esophageal cancer: An intergroup study. J Clin Oncol 1997; 15: 277-84.
4. Cooper J S, Guo M D, Herskovic A et al. chemoradiotherapy of locally advanced esophageal cancer: Long-term follow-up of a prospective randomized trial (RTOG 85-01). JAMA 1999; 281: 1623-7.
5. Ohtsu A, Boku N, Muro K et al. Definitive chemoradiotherapy for T4 and/ or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol 1999; 17: 2915-21.
6. Nishimura Y, Suzuki M, Nakamatsu K et al. Prospective trial of concurrent chemoradiotherapy with protracted infusion of 5-fluorouracil and cisplatin for T4 esophageal cancer with or without fistula. Int J Radiat Oncol Biol Phys 2002; 53: 134-9.
7. Kaneko K, Ito H, Konishi K et al. Definitive chemoradiotherapy for patients with malignant stricture due to T3 or T4 squamous cell carcinoma of the esophagus. Br J Cancer 2003; 88: 18-24.
8. Crosby TD, Brewster AE, Borley A et al. Definitive chemoradiation in patients with inoperable oesophagus carcinoma. Br J Cancer 2004; 90: 70-5.
9. Vaupel P, Hockel M. Tumor hypoxia and therapeutic resistance. In: Nowrousian M R, (ed.). Recombinant Human Erythropoietin (Rhepo) in Clinical Oncology: Berlin. Heidenberg. New York: Springer, 2002: 127-46.
10. Nordsmark M, Overgaard M, Overgaard J et al. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 1996; 41: 31-9.
11. Brizel D M, Dodge R K, Clough R W et al. Oxygenation of head and neck cancer: Changes during radiotherapy and impact on treatment outcome. Radiother Oncol 1999; 53: 113-17.
12. Rudat V, Vanselow B, Wollensack P et al. Repeatability and prognostic impact of the pretreatment pO(2) histography in patients with advanced head and neck cancer. Radiother Oncol 2000; 57: 31-7.
13. Nordsmark M, Bentzen S M, Rudat V et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 2005; 77: 18-24.
14. Hockel M, Schlenger K, Arai B et al. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996; 56: 4509-15.
15. Hockel M, Knoop C, Schlenger K et al. Intratumoral pO2 predicts survival in advanced cancer of uterine cervix. Radiother Oncol 1993; 26: 45-50.
16. Koncke T H, Weitmann H D, Feldmann H J, Selzer E, Potter R, Mitze M. Intratumoral pO2 measurements as predictive assay in the treatment of carcinoma of the uterine cervix. Radiother Oncol 1999; 53: 99-104.
17. Hochel M, Vorndran B, Schlenger K et al. Tumor oxygenation: A new predictive parameter in locally advanced cancer of the uterine cervix. Gynecol Oncol 1993; 51: 141-9.
18. Fyles A W, Milosevic M, Wong R et al. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol 1998; 48: 149-56.
19. Sundfor K, Lyng H, Trope C G et al. Intratumoral pO2-measurements as predictive assay in the treatment of carcinoma of the cervix. Br J Cancer 1998; 78: 822-7.
20. Sundfor K, Lyng H, Trope C G et al. Treatment outcome in advanced squamous cell carcinoma of the uterine cervix: Relationships to pretreatment tumor oxygenation and vascularization. Radiother Oncol 2000; 54: 101-7.
21. Fein D A, Lee W R, Hanlon A L et al. Pretreatment hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx. J Clin Oncol 1995; 13: 2077-83.
22. Dubray B, Mosseri V, Brunin F et al. Anemia is associated with lower local-regional control and survival after radiation therapy for head and neck cancer: A prospective study. Radiology 1996; 201: 553-8.
23. Grigiene R, Aleknavicius E, Kurtinaitis J. Prognostic value of anemia for patients with cervical treated with irradiation. Medicina (Kaunas) 2005; 41: 916-24.
24. MacRae R, Shyr Y, Johnson D et al. Declining hemoglobin during chemoradiotherapy for locally advance non-small cell lung cancer is significant. Radiother Oncol 2002; 64: 37-60.
25. Langendijk H, de Jong J, Wanders R et al. The importance of pre-treatment haemoglobin level in inoperable non-small cell lung carcinoma treated with radical radiotherapy. Radiother Oncol 2003; 67: 321-5.
26. Duffaud F, Therasse P. New guidelines to evaluate the response to treatment in solid tumors. Bull Cancer 2000; 87: 881-6.
27. Tahara M, Ohtsu A, Hironaka S et al. Clinical impact of criteria for complete response (CR) of primary site to treatment of esophageal cancer. Jpn J Clin Oncol 2005; 35: 316-23.
28. Kaplan E L, Meire P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
29. Moulder J E, Rockwell S. Tumor hypoxia: Its impact on cancer therapy. Cancer Metastasis Rev 1987; 5: 313-41.
30. Rockwell S, Moulder J E. Hypoxic fractions of human tumor xenografted into mice: A review. Int J Radiat Oncol Biol Phys 1990; 19: 197-202.
31. Palcic B, Skarsgard L D. Reduced oxygen enhancement ratio at low doses of ionizing radiation. Radiat Res 1984; 100: 328-39.
32. Teicher B A, Holden S A, al-Achi A et al. Classification of anti-neoplastic treatments by the differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in FSaHC murine fibrosarcoma. Cancer Res 1990; 50: 3339-44.
33. Green S L, Giaccia A J. Tumor hypoxia and the cell cycle: Implications for malignant progression and response to therapy. Cancer J Sci Am 1998; 4: 218-23.
34. Varlotto J, Stevenson M A. Anemia, tumor hypoxia, and the cancer patient. Int J Radiat Oncol Biol Phys 2005; 63: 25-36.
35. Vaupel P, Harrison L. Tumor hypoxia: Causative factors, compensatory mechanisms, and cellular response. Oncologist 2004; 9: 4-9.
36. Hall E J. Predictive assays. In:
37. Hall E J, Giaccia A J, eds. Radiology for the Radiologist. New York: Lippincott, Williams and Wilkins. 1994: 130-50.
38. Dunst J, Kuhnt T, Strauss H G et al. Anemia in cervical cancers: Impact on survival, patterns of relapse, and association with hypoxia and angiogenesis. Int J Radat Oncol Biol Phys 2003; 56: 778-87.
39. Hironaka S, Hasebe T, Kamijo T et al. Biopsy specimen microvessel density is a useful prognostic marker in patients with T2-4M0 esophageal cancer treated with chemoradiotherapy. Clin Cancer Res 2002; 8: 124-30.
40. Kamijo T, Yokose T, Hasebe T et al. Potential role of microvessel density in predicting radiosensitivity of T1 and T2 stage laryngeal squamous cell carcinoma treated with radiotherapy. Clin Cancer Res 2000; 6: 3159-65.
41. Denis F, Garaud P, Bardet E et al. Final results of the 94-01 French head and neck oncology and radiotherapy group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 2004; 22: 69-76.
42. Schafer U, Micke O, Muller S B et al. Hemoglobin as an independent prognostic factor in the radiotherapy of head and neck tumors. Strahlenther Onkol 2003; 179: 527-34.
43. Grogan M, Thomas G M, Melamed I et al. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer 1999; 86: 1528-36.
44. Altun M, Demiral A N, Meral R et al. Prognostic significance of hemoglobin concentration in nasopharyngeal carcinoma: Does treatment-induced anemia have a negative effect? In Vivo 2003; 17: 483-7.
45. Obermair A, Cheuk R, Horwood K et al. Impact of hemoglobin levels before and during concurrent chemoradiotherapy on the response of treatment in patients with cervical carcinoma: Preliminary results. Cancer 2001; 92: 903-8.